Home › Research › Drug development
Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics
Gupta T, Kaur M, Shekhawat D, Aggarwal R, Nanda N, Sahni D.. Basic and clinical neuroscience, 2023-05-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction Emerging evidence has shown that the glucagon-like peptide-1 (GLP-1) agonist can be used to treat Alzheimer disease; however, knowledge of its neural targets is limited. Results GLP-1 expression was observed in most of the cortical areas (maximum in frontal, prefrontal and parietal cortex), diencephalon, and brainstem, but not in the cerebellum. Protein expression studies validated these results. Hippocampus demonstrated a significant presence of GLP-1R but patchy immunoreactivity to GLP-1 . GLP-1 demonstrated an age-related decline in most of the areas after the fifth decade. GLP-1 gene expression was seen in cortical areas, diencephalon and brainstem, but not in cerebellum.Hippocampus demonstrated significant presence of GLP-1R but patchy immunoreactivity to GLP-1 . GLP-1 demonstrated age related decline in most of the areas after fifth decade.A detailed description of GLP-1 and amp; GLP-1R locations was given which may lead to novel treatment options. Plain language summary Emerging evidence has shown that the glucagon like peptide-1 ( GLP1-1 ) agonist can be used for treating Alzheimer's disease but knowledge of its neural targets is limited. Protein expression studies validated these results. Hippocampus demonstrated significant presence of GLP-1R but patchy immunoreactivity to GLP-1 . GLP-1 demonstrated age related decline in most of the areas after 5 th decade.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gupta, T., Kaur, M., Shekhawat, D., Aggarwal, R., Nanda, N., & Sahni, D. (2023). Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics. Basic and clinical neuroscience. https://doi.org/10.32598/bcn.2021.2554.2
Vancouver
Gupta T, Kaur M, Shekhawat D, Aggarwal R, Nanda N, Sahni D. Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics. Basic and clinical neuroscience. 2023. doi:10.32598/bcn.2021.2554.2. PMID: 38077175.
BibTeX
@article{gupta2023-38077175,
author = {Gupta, T. and Kaur, M. and Shekhawat, D. and Aggarwal, R. and Nanda, N. and Sahni, D.},
title = {{Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics}},
journal = {Basic and clinical neuroscience},
year = {2023},
doi = {10.32598/bcn.2021.2554.2},
pmid = {38077175},
url = {https://doi.org/10.32598/bcn.2021.2554.2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Introduction Emerging evidence has shown that the glucagon-like peptide-1 (GLP-1) agonist can be used to treat Alzheimer disease; however, knowledge of its neural targets is limited.
- Results GLP-1 expression was observed in most of the cortical areas (maximum in frontal, prefrontal and parietal cortex), diencephalon, and brainstem, but not in the cerebellum.
- Protein expression studies validated these results.
- Hippocampus demonstrated a significant presence of GLP-1R but patchy immunoreactivity to GLP-1 .
- GLP-1 demonstrated an age-related decline in most of the areas after the fifth decade.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Basic and clinical neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38077175) |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “brain-distribution”
2 studies in the library carry the topic tag “brain-distribution”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.